GlassScriptPhysician profile
Jesheeja Kuniyil
NPI 1518291574
$3,544.13
in general payments reported to CMS, 2019-2025
17 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $442 · 2021: $224 · 2022: $402 · 2023: $596 · 2024: $674 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,065.71 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $543.85 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $466.69 | 2019-2025 | Dificid, Zerbaxa, Verquvo |
| Alexion Pharmaceuticals, INC. | $290.02 | 2021-2025 | Ultomiris, Soliris |
| Abbvie INC. | $270.49 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.32 | 2020-2025 | Jardiance |
| Inari Medical, INC. | $123.69 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.69 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $91.82 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $88.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $74.59 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $69.15 | 2025 | Vowst |
| Novartis Pharmaceuticals Corporation | $53.87 | 2020-2021 | |
| Shionogi INC | $40.58 | 2023 | Fetroja |
| Fisher & Paykel Healthcare INC | $23.92 | 2023 | Fisher & Paykel Healthcare |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $19.45 | 2019 | |
| La Jolla Pharmaceutical Company | $15.99 | 2025 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesheeja Kuniyil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.